Eduardo Ruman (In Memoriam)
Diretor-Presidente
Administrativo e Empreendedor
Denise Ruman
MTB - 0086489
JORNALISTA RESPONSÁVEL
The Biggest and Best International Newspaper for World Peace
BRANCH OFFICE of PACIFIST JOURNAL in LATIN AMERICA
Founder, President And International General Chief-Director / Fundadora, Presidente e Diretora Geral Internacional :  Denise Ruman - MTB: 0086489 / SP-BRAZIL
Local Chief-Director - Brazil / Diretora-Chefe Local - Brasil :  Denise Ruman
Mentor do Jornal / Mentor of the Newspaper  :  José Cardoso Salvador (in memoriam)
Mentor-Director / Mentor-Director  :  Mahavátar Babají (in memoriam)

Saúde / 14/06/2021

COVID 19 NEWS

Novavax Vaccine Announces Efficacy of 93.2% Against Variants

0 votes
Novavax Vaccine Announces Efficacy of 93.2% Against Variants

Fonte SCIENCE

The company Novavax, announced this Monday, 14, results of a clinical trial that shows 90.4% overall effectiveness of its vaccine against symptomatic infections by COVID-19 and 100% protection against moderate and severe diseases.

The study was carried out with 30,000 people in the US and Mexico and published in the scientific journal Science.

The vaccine, which uses a different technology than the COVID-19 vaccines authorized so far, showed results against eight viral variants of interest and concern, with an efficacy of 93.2%. And the study says the vaccine is safe and well tolerated.

“This vaccine looks phenomenal. I'm excited about these results,” said Monica Gandhi, an infectious disease physician and epidemiologist at the University of California, San Francisco.

the effectiveness

The difference of a few percentage points between the 90% efficacy of Novavax and the 95% and 94% efficacy of Pfizer / BioNTech and Moderna vaccines is explained in part by Novavax's later trial, which tested the vaccine against viral variants, says John Moore, an immunologist at Weill Cornell Medicine and a participant in the Novavax study.

Testing of vaccines other companies, composed of messenger RNA (mRNA), was completed before such variants were widely circulating.

"This is a vaccine whose effectiveness is at least equivalent to that of Pfizer and Moderna," said Moore. "It's essentially 100% protective against disease."

clinical study

The clinical trial was highly diverse, with 44% non-white participants.

And simple vaccine storage requirements could speed up access to it in remote communities around the globe.

FDA

Novavax plans to apply to the Food and Drug Administration (FDA) – the US Food and Drug Administration – and other regulators for an emergency use authorization in the third quarter.

The company has yet to complete regulatory requirements to ensure its product consistently matches the vaccine used in clinical trials, said President and CEO Stanley Erck.


Comentários
0 comentários


  • Enviar Comentário
    Para Enviar Comentários é Necessário estar Logado.
    Clique Aqui para Entrar ou Clique Aqui para se Cadastrar.

Ainda não Foram Enviados Comentários!
  • ESPAÇO PUBLICITÁRIO
  • ESPAÇO PUBLICITÁRIO
  • ESPAÇO PUBLICITÁRIO
  • ESPAÇO PUBLICITÁRIO
  • ESPAÇO PUBLICITÁRIO
  • ESPAÇO PUBLICITÁRIO
  • ESPAÇO PUBLICITÁRIO
  • ESPAÇO PUBLICITÁRIO
  • ESPAÇO PUBLICITÁRIO

Copyright 2021 - Jornal Pacifista - Todos os direitos reservados. powered by WEB4BUSINESS

Inglês Português Frances Italiano Alemão Espanhol Árabe Bengali Urdu Esperanto Croata Chinês Coreano Grego Hebraico Japonês Hungaro Latim Persa Polonês Romeno Vietnamita Swedish Thai Czech Hindi Você